<DOC>
	<DOC>NCT00425919</DOC>
	<brief_summary>The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.</brief_summary>
	<brief_title>Study Evaluating PPM-204 In Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>The objectives of the study are to identify doses of PPM-204 that are therapeutically effective and well tolerated in improving glycemic control over 24 weeks of treatment in subjects with type 2 diabetes mellitus (T2DM).</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Men and women of nonchildbearing potential, 18 to 70 years old Subjects currently treated with diet and exercise alone and subjects receiving a single oral antidiabetic medication BMI &gt; 23 and &lt; 43 For subjects currently treated with 1 antidiabetic medication: HbA1c is greater than or equal to 6.8% and less than or equal to 8.5%. For subjects not currently treated with antidiabetic medications: HbA1c is greater than or equal to 7.2% and less than or equal to 9.0% Subjects requiring insulin therapy Subjects currently receiving 2 or more oral antidiabetic medications Subjects requiring systemic corticosteroids, unless treatment was discontinued at least 4 weeks before the screening visit Subjects receiving warfarin Subjects currently receiving thiazolidinediones, unless treatment was discontinued 8 weeks before the screening visit Significant diabetic complications (retinopathy, nephropathy, symptomatic neuropathy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Diabetes</keyword>
</DOC>